• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

No survival benefit with everolimus treatment for hepatocellular carcinoma [EVOLVE-1 Trial]

byReshmi MadankumarandPriyanka Vedak
July 1, 2014
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Compared to placebo, treatment with everolimus did not improve survival in patients with advanced hepatocellular carcinoma (HCC) who had previously failed sorafenib treatment. 

2. Compared to placebo, everolimus treatment did not delay time to disease progression but did improve the disease control rate. 

Evidence Rating Level: 1 (Excellent)       

Study Rundown: Advanced hepatocellular carcinoma (HCC) portends a poor prognosis due to the dearth of current available therapies. Sorafenib is the only treatment proven to improve survival in HCC. However, it demonstrates moderate efficacy and has been associated with numerous adverse events. Everolimus is a new medication that is under investigation for the treatment of HCC that acts by inhibiting the mTOR pathway.

This phase 3 clinical trial measured the survival of patients with advanced HCC after disease progression with sorafenib or intolerance to sorafenib treatment who were subsequently treated with either everolimus or placebo. There was no survival benefit or delay in time to disease progression detected with everolimus treatment compared to placebo. While the disease control rate was improved in the everolimus group compared to that of the placebo group, no complete responses to therapy were observed.

The relationship between individual molecular characteristics or biomarkers and response to various targeted therapies for HCC remains unknown. Thus, it is possible that select patient populations may benefit from this treatment. Nevertheless, this study does not demonstrate a survival benefit with everolimus treatment in advanced HCC at this time.

Click to read the study, published today in JAMA

RELATED REPORTS

Hepatic arterial phase imaging more sensitive than portal venous phase in the detection of hepatic lesions and arterioportal shunting [Classics Series]

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

Relevant Reading: Targeted systemic therapies for hepatocellular carcinoma: Clinical perspectives, challenges and implications

In-Depth [randomized controlled trial]: This study was a randomized controlled double-blind phase 3 study in which patients with advanced HCC and treatment failure or intolerance to sorafenib were randomized to treatment with everolimus (n=362) or placebo (n=184). Patients received 7.5 mg daily of everolimus or placebo with best supportive care for a median follow-up of 24.6 months. Median survival was 7.6 months (95%CI, 6.7-8.7) for the everolimus group and 7.3 months (95%CI, 6.3-8.7) for the placebo group, heralding no difference in the risk of death between the two groups (HR 1.05, 95%CI 0.86-1.27, p=.68). However, patients with Hepatitis B virus as the etiology of HCC had improved survival with everolimus (HR 0.64, 95%CI 0.45-0.93) compared to other etiologies. There was no improvement in time to progression between the two groups (HR 0.93, 95%CI 0.75-1.15). The disease control rate was 56.1% with everolimus compared to 45.1% with placebo but the significance of this finding must be interpreted in the context of the other results.

More from this author: Prophylactic implantable cardioverter-defibrillators may decrease mortality in left ventricular dysfunction, The VIDA trial: Vitamin D3 does not improve outcomes in asthma patients

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: everolimushepatocellular carcinomasorafenib
Previous Post

Increased multiple sclerosis relapse after natalizumab (Tysabri) discontinuation (TY-STOP Study)

Next Post

Whole exome sequencing effective at identifying mitochondrial pathogenic mutations

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Hepatic arterial phase imaging more sensitive than portal venous phase in the detection of hepatic lesions and arterioportal shunting [Classics Series]

August 5, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

OPTN and UNOS update policy regarding hepatocellular carcinoma [Classics Series]

June 30, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Radiofrequency thermal ablation superior to percutaneous ethanol injection in hepatocellular carcinoma [Classics Series]

June 30, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Hematology/Oncology Classics

Arterial chemoembolization improves survival in non-resectable hepatocellular carcinoma [Classics Series]

June 29, 2022
Next Post
BRAF V600E mutations linked with increased mortality in thyroid cancer

Whole exome sequencing effective at identifying mitochondrial pathogenic mutations

Stem cell transplant may be effective in sickle cell disease

Stem cell transplant may be effective in sickle cell disease

2 Minute Medicine Rewind January 13-19, 2014

Tenofovir prophylaxis linked with reduced risk of herpes simplex 2

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Factors associated with breastfeeding rates in Canada
  • Efanesoctocog alfa is efficacious in treating severe hemophilia A
  • Mavacamten associated with improvement in submaximal exertional tolerance: A secondary analysis of the EXPLORER-HCM randomized trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options